| Year |
Citation |
Score |
| 2023 |
Bowman KR, Lu P, Lim C. p53-Bad* in a Hepatocellular Carcinoma Mouse Model. Biorxiv : the Preprint Server For Biology. PMID 37425886 DOI: 10.1101/2023.06.29.547129 |
0.307 |
|
| 2023 |
Constance JE, McFarland MM, Casucci T, Deininger MW, Enioutina EY, Job K, Lemons RS, Lim CS, Ward RM, Yellepeddi V, Watt KM. Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. Jmir Research Protocols. 12: e38167. PMID 37213193 DOI: 10.2196/38167 |
0.633 |
|
| 2022 |
Bowman KER, Ahne L, O'Brien L, Vander Mause ER, Lu P, Wallis B, Evason KJ, Lim CS. p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma. Molecular Pharmaceutics. PMID 36490361 DOI: 10.1021/acs.molpharmaceut.2c00665 |
0.363 |
|
| 2019 |
Lu P, Redd Bowman KE, Brown SM, Joklik-Mcleod M, Vander Mause ER, Nguyen HTN, Lim CS. p53-Bad: A Novel Tumor Suppressor/Proapoptotic Factor Hybrid Directed to the Mitochondria for Ovarian Cancer Gene Therapy. Molecular Pharmaceutics. PMID 31241338 DOI: 10.1021/Acs.Molpharmaceut.9B00136 |
0.554 |
|
| 2019 |
Lu P, Vander Mause ER, Redd Bowman KE, Brown SM, Ahne L, Lim CS. Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53. Journal of Ovarian Research. 12: 45. PMID 31092272 DOI: 10.1186/S13048-019-0516-2 |
0.555 |
|
| 2019 |
Bowman KR, Kim JH, Lim CS. Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer. Journal of Ovarian Research. 12: 38. PMID 31039796 DOI: 10.1186/S13048-019-0514-4 |
0.475 |
|
| 2018 |
Cornillie SP, Bruno BJ, Lim CS, Cheatham TE. Computational Modeling of Stapled Peptides Towards a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics. The Journal of Physical Chemistry. B. PMID 29519125 DOI: 10.1021/Acs.Jpcb.8B01014 |
0.333 |
|
| 2016 |
Bruno BJ, Cornillie SP, Cheatham TE, Chou DH, Lim CS. Abstract 3817: Recombinant stapled proteins for the treatment of chronic myeloid leukemia Cancer Research. 76: 3817-3817. DOI: 10.1158/1538-7445.Am2016-3817 |
0.386 |
|
| 2016 |
Lu P, Lim CS. Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer Cancer Research. 76: 3500-3500. DOI: 10.1158/1538-7445.Am2016-3500 |
0.586 |
|
| 2015 |
Lu P, Bruno BJ, Rabenau M, Lim CS. Delivery of drugs and macromolecules to the mitochondria for cancer therapy. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26482081 DOI: 10.1016/J.Jconrel.2015.10.023 |
0.41 |
|
| 2015 |
Bruno BJ, Lim CS. Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide. Molecular Pharmaceutics. 12: 1412-21. PMID 25858426 DOI: 10.1021/Mp500701U |
0.404 |
|
| 2015 |
Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, O'Hare T, Deininger MW, Lim CS. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia. PMID 25721898 DOI: 10.1038/Leu.2015.53 |
0.366 |
|
| 2014 |
Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janát-Amsbury MM, Lim CS. Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model. Gene Therapy. 21: 903-12. PMID 25077773 DOI: 10.1038/Gt.2014.70 |
0.81 |
|
| 2014 |
Okal A, Cornillie S, Matissek SJ, Matissek KJ, Cheatham TE, Lim CS. Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity. Molecular Pharmaceutics. 11: 2442-52. PMID 24836513 DOI: 10.1021/Mp500202P |
0.818 |
|
| 2014 |
Matissek KJ, Okal A, Mossalam M, Lim CS. Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax. Pharmaceutical Research. 31: 2503-15. PMID 24633417 DOI: 10.1007/S11095-014-1346-Y |
0.808 |
|
| 2013 |
Matissek KJ, Mossalam M, Okal A, Lim CS. The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria. Molecular Pharmaceutics. 10: 3592-602. PMID 23968395 DOI: 10.1021/Mp400380S |
0.832 |
|
| 2013 |
Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim CS. A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells. Molecular Pharmaceutics. 10: 3922-33. PMID 23964676 DOI: 10.1021/Mp400379C |
0.802 |
|
| 2013 |
Miller GD, Woessner DW, Sirch MJ, Lim CS. Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML. Molecular Pharmaceutics. 10: 3475-83. PMID 23915432 DOI: 10.1021/Mp400323C |
0.379 |
|
| 2013 |
Reaz S, Mossalam M, Okal A, Lim CS. A single mutant, A276S of p53, turns the switch to apoptosis. Molecular Pharmaceutics. 10: 1350-9. PMID 23402381 DOI: 10.1021/Mp300598K |
0.798 |
|
| 2013 |
Davis JR, Mossalam M, Lim CS. Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2. Molecular Pharmaceutics. 10: 1340-9. PMID 23398638 DOI: 10.1021/Mp300543T |
0.814 |
|
| 2013 |
Mossalam M, Soto J, Lim CS, Abel ED. Solid phase synthesis of mitochondrial triphenylphosphonium-vitamin E metabolite using a lysine linker for reversal of oxidative stress. Plos One. 8: e53272. PMID 23341934 DOI: 10.1371/Journal.Pone.0053272 |
0.749 |
|
| 2013 |
Woessner DW, Lim CS. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation. Molecular Pharmaceutics. 10: 270-7. PMID 23211037 DOI: 10.1021/Mp300405N |
0.394 |
|
| 2013 |
Matissek KJ, Mossalam M, Okal A, Lim CS. Abstract 791: Targeting small domains of p53 to mitochondrial Bcl-XL for cancer therapy. Cancer Research. 73: 791-791. DOI: 10.1158/1538-7445.Am2013-791 |
0.833 |
|
| 2013 |
Okal A, Mossalam M, Matissek KJ, Lim CS. Abstract 790: An alternative tetramerization domain of p53 for exclusive homo-oligomerization and potent tumor suppression. Cancer Research. 73: 790-790. DOI: 10.1158/1538-7445.Am2013-790 |
0.808 |
|
| 2013 |
Miller GD, Woessner DW, Lim CS. Abstract 2170: Development of a "dual-hit" combination therapy for CML. Cancer Research. 73: 2170-2170. DOI: 10.1158/1538-7445.Am2013-2170 |
0.387 |
|
| 2013 |
Okal A, Reaz S, Lim CS. Cancer biology: Some causes for a variety of different diseases Cancer Targeted Drug Delivery: An Elusive Dream. 121-159. DOI: 10.1007/978-1-4614-7876-8_5 |
0.732 |
|
| 2012 |
Constance JE, Woessner DW, Matissek KJ, Mossalam M, Lim CS. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Molecular Pharmaceutics. 9: 3318-29. PMID 22957899 DOI: 10.1021/Mp3003539 |
0.788 |
|
| 2012 |
Constance JE, Lim CS. Targeting malignant mitochondria with therapeutic peptides. Therapeutic Delivery. 3: 961-79. PMID 22946430 DOI: 10.4155/Tde.12.75 |
0.731 |
|
| 2012 |
Davis JR, Mossalam M, Lim CS. Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction. Pharmaceutical Research. 29: 3455-63. PMID 22869106 DOI: 10.1007/S11095-012-0840-3 |
0.769 |
|
| 2012 |
Constance JE, Despres SD, Nishida A, Lim CS. Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells. Pharmaceutical Research. 29: 2317-28. PMID 22549737 DOI: 10.1007/S11095-012-0758-9 |
0.741 |
|
| 2012 |
Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE, Lim CS. Correction to "improved coiled-coil design enhances interaction with bcr-abl and induces apoptosis". Molecular Pharmaceutics. 9: 1535. PMID 22444272 DOI: 10.1021/Mp300089A |
0.76 |
|
| 2012 |
Mossalam M, Matissek KJ, Okal A, Constance JE, Lim CS. Direct induction of apoptosis using an optimal mitochondrially targeted p53. Molecular Pharmaceutics. 9: 1449-58. PMID 22380534 DOI: 10.1021/Mp3000259 |
0.803 |
|
| 2012 |
Dixon AS, Constance JE, Tanaka T, Rabbitts TH, Lim CS. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs. Pharmaceutical Research. 29: 1098-109. PMID 22183511 DOI: 10.1007/S11095-011-0654-8 |
0.788 |
|
| 2012 |
Dixon AS, Miller GD, Bruno BJ, Constance JE, Woessner DW, Fidler TP, Robertson JC, Cheatham TE, Lim CS. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Molecular Pharmaceutics. 9: 187-95. PMID 22136227 DOI: 10.1021/Mp200461S |
0.785 |
|
| 2012 |
Woessner DW, Lim CS. Abstract 5615: Combination therapy for chronic myelogenous leukemia: Targeting the BCR-ABL coiled-coil domain and other pathways for synthetic lethality Cancer Research. 72: 5615-5615. DOI: 10.1158/1538-7445.Am2012-5615 |
0.346 |
|
| 2012 |
Matissek KJ, Mossalam M, Okal A, Lim CS. Abstract 1182: Targeting p53 to mitochondrial outer membrane using the Bcl-XL signal causes p53 specific apoptosis Cancer Research. 72: 1182-1182. DOI: 10.1158/1538-7445.Am2012-1182 |
0.827 |
|
| 2012 |
Okal A, Mossalam M, Matissek KJ, Lim CS. Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells Cancer Research. 72: 1176-1176. DOI: 10.1158/1538-7445.Am2012-1176 |
0.811 |
|
| 2011 |
Dixon AS, Pendley SS, Bruno BJ, Woessner DW, Shimpi AA, Cheatham TE, Lim CS. Disruption of Bcr-Abl coiled coil oligomerization by design. The Journal of Biological Chemistry. 286: 27751-60. PMID 21659527 DOI: 10.1074/Jbc.M111.264903 |
0.626 |
|
| 2011 |
Woessner DW, Dixon AS, Lim CS. Abstract 1780: Potentiating chronic myeloid leukaemia treatment using oligomeric disruption and RNAi Cancer Research. 71: 1780-1780. DOI: 10.1158/1538-7445.Am2011-1780 |
0.653 |
|
| 2010 |
Mossalam M, Dixon AS, Lim CS. Controlling subcellular delivery to optimize therapeutic effect. Therapeutic Delivery. 1: 169-93. PMID 21113240 DOI: 10.4155/Tde.10.8 |
0.766 |
|
| 2010 |
Dixon AS, Lim CS. The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain. Biotechniques. 49: 519-24. PMID 20615205 DOI: 10.2144/000113452 |
0.609 |
|
| 2009 |
Dixon AS, Kakar M, Schneider KM, Constance JE, Paullin BC, Lim CS. Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis. Journal of Controlled Release : Official Journal of the Controlled Release Society. 140: 245-9. PMID 19576252 DOI: 10.1016/J.Jconrel.2009.06.026 |
0.794 |
|
| 2007 |
Kakar M, Davis JR, Kern SE, Lim CS. Optimizing the protein switch: altering nuclear import and export signals, and ligand binding domain. Journal of Controlled Release : Official Journal of the Controlled Release Society. 120: 220-32. PMID 17574289 DOI: 10.1016/J.Jconrel.2007.04.017 |
0.355 |
|
| 2007 |
Kakar M, Cadwallader AB, Davis JR, Lim CS. Signal sequences for targeting of gene therapy products to subcellular compartments: the role of CRM1 in nucleocytoplasmic shuttling of the protein switch. Pharmaceutical Research. 24: 2146-55. PMID 17562146 DOI: 10.1007/S11095-007-9333-1 |
0.331 |
|
| 2007 |
Davis JR, Kakar M, Lim CS. Controlling protein compartmentalization to overcome disease. Pharmaceutical Research. 24: 17-27. PMID 16969692 DOI: 10.1007/S11095-006-9133-Z |
0.314 |
|
| 2006 |
Kakar M, Kanwal C, Davis JR, Li H, Lim CS. Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains. The Aaps Journal. 8: E718-28. PMID 17233535 DOI: 10.1208/Aapsj080481 |
0.769 |
|
| 2005 |
Li H, Fidler ML, Lim CS. Effect of initial subcellular localization of progesterone receptor on import kinetics and transcriptional activity. Molecular Pharmaceutics. 2: 509-18. PMID 16323958 DOI: 10.1021/Mp0500418 |
0.358 |
|
| 2004 |
Kanwal C, Mu S, Kern SE, Lim CS. Bidirectional on/off switch for controlled targeting of proteins to subcellular compartments. Journal of Controlled Release : Official Journal of the Controlled Release Society. 98: 379-93. PMID 15312994 DOI: 10.1016/J.Jconrel.2004.05.008 |
0.782 |
|
| 2002 |
Kanwal C, Li H, Lim CS. Model system to study classical nuclear export signals. Aaps Pharmsci. 4: E18. PMID 12423067 DOI: 10.1208/Ps040318 |
0.78 |
|
| 2001 |
Baumann CT, Ma H, Wolford R, Reyes JC, Maruvada P, Lim C, Yen PM, Stallcup MR, Hager GL. The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Molecular Endocrinology (Baltimore, Md.). 15: 485-500. PMID 11266502 DOI: 10.1210/Mend.15.4.0618 |
0.36 |
|
| 1999 |
Lim CS, Baumann CT, Htun H, Xian W, Irie M, Smith CL, Hager GL. Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras. Molecular Endocrinology (Baltimore, Md.). 13: 366-75. PMID 10076994 DOI: 10.1210/Mend.13.3.0247 |
0.331 |
|
| Show low-probability matches. |